HOME >> MEDICINE >> NEWS
Infectious disease researchers develop basis for experimental melanoma treatment

While investigating a fungus known to cause an infection in people with AIDS, two grantees of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), unexpectedly discovered a potential strategy for treating metastatic melanoma, one of the deadliest forms of skin cancer. The treatment approach, which involves combining an antibody with radiation, has since been further developed and is expected to enter early-stage human clinical studies in 2007.

"This is an excellent example of how scientific research in one discipline may have payoffs in a completely unpredictable way," says NIAID Director Anthony S. Fauci, M.D. "This important AIDS-related research has led to the development of a promising therapeutic strategy for a terrible cancer that affects thousands of people each year."

Arturo Casadevall, M.D., Ph.D., of the Albert Einstein College of Medicine at Yeshiva University, in New York City, and his research team began studying the biology of the skin pigment melanin to better understand why its synthesis plays a role in the process whereby certain yeast-like fungi, specifically Cryptococcus neoformans, cause disease in some people. C. neoformans can cause cryptococcosis, a potentially fatal fungal infection that can lead to inflammation of the brain and death in people with AIDS and other immunocompromised individuals.

The researchers created an infection-fighting antibody, known as a monoclonal antibody, that binds to melanin based on scientific evidence suggesting that when melanin is synthesized, it causes the immune system to react in a way that might create antibodies to fend off C. neoformans infection. Based on this finding, Dr. Casadevall theorized that melanomas might contain melanin that would allow the monoclonal antibody to deliver radiation to tumor cells. Dr. Casadevall then teamed with his colleague Ekaterina Dadachova, Ph.D., an expert in nuclear medicine a
'"/>

Contact: Kathy Stover
kstover@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
7-Dec-2006


Page: 1 2 3

Related medicine news :

1. Infectious disease doctors respond to President Bushs strategy on pandemic influenza
2. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
3. Smoking may strongly increase long-term risk of eye disease
4. Pot bellies linked to early signs of cardiovascular disease
5. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
6. 1 of 2 pediatric kidney disease research centers in world established
7. Reductive stress linked to heart disease
8. Obesity linked to hyperparathyroidism in chronic kidney disease
9. Wireless technology shows promise in diagnosing pediatric intestinal disease
10. Researchers link metal ions to neurodegenerative disease
11. Green tea holds promise as new treatment for inflammatory skin diseases

Post Your Comments:
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency Foundation (IDF) ... community using its IDF ePHR, an electronic personal health record powered by Get ... easily track their health information, including symptoms, diagnoses, medications, infusions and other critical ...
(Date:7/7/2015)... ... 07, 2015 , ... Parents and guardians of teenagers or young adults will ... holistic treatment center for drug and alcohol abuse located in Southwest Michigan. A recently ... shown a significant increase in the “club drug” use among high school seniors. The ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... of telemedicine programs in communities throughout Georgia, announces the launch of the first ... rural communities of Hancock County, GA. The new program will not only provide ...
(Date:7/7/2015)... NH (PRWEB) , ... July ... ... integrated, full-service public relations, marketing, and creative design firm, today announced that ... regional public relations and social media campaign, content strategy, and marketing launch ...
(Date:7/7/2015)... Horsham, PA (PRWEB) , ... July 07, 2015 ... ... seasoned financial executive Ellen Purdy as the company’s new Chief Financial Officer, effective ... financial and leadership experience in companies ranging from a multi-billion dollar, global chemical ...
Breaking Medicine News(10 mins):Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:Office Practicum Announces new CFO 2
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
(Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
Cached News: